During the secondary analysis, the much less conservative but clinically meaningful criterion of secure response (described for a 50% or more reduction in MADRS from baseline for 2 weeks) was used. With the patients who realized steady response, twenty five.8% from the esketamine group and 57.6% during the placebo group https://menachemj666esi3.blgwiki.com/user